An interventional study of SYNOLIS VA 80/160 in Osteoarthritis, Hip, sponsored by Aptissen SA. Recruiting at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Aptissen SA · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Osteoarthritis, Hip with a site in France — 10 open to participants now, 16 under way, none of them phase 3. Osteoarthritis, Hip · France.
Among the 38 studies in Osteoarthritis, Hip with a site in France, this one is the 15th largest by planned enrollment of the 20 interventional ones that give a count, is one of 7 that started in 2024, is one of 11 with no phase, reaches primary completion later than 9 of the 15 other live ones, and was the 31st registered.
642 studies on the registry are indexed under Osteoarthritis, Hip; 120 are open to participants now.
Browse Osteoarthritis, Hip studies →10 of the 38 studies in Osteoarthritis, Hip with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Medacta International SA · Sites in France
Ages 18–85
University Hospital, Lille · Sites in France
Ages 18+
Lille Catholic University · Sites in France
Ages 18+
University Hospital, Clermont-Ferrand · Sites in France
Ages 50–70
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 86 Osteoarthritis, Hip studies recruiting now, 53 (62%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 7 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is below the median of 90 across 458 interventional studies indexed under Osteoarthritis, Hip.
Median enrollment 130 across the 20 interventional studies, 250 across the 17 observational. Of the 15 that completed or were terminated, 3 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 38 have an industry lead sponsor. The 10 most frequent:
Aptissen SA is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Aptissen SA has 1 study filed under Osteoarthritis, Hip — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteoarthritis, Hip with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
| NCT05829733Aptissen SA6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis | 2027-04 |
| NCT06258369Lille Catholic UniversityGait Initiation and Transition From Double to Single Support in Patients With Unilateral Primary Coxarthrosis | 2027-08-19 |
Add all 3 to your calendar (.ics) → With an account.
Among the 38 studies in Osteoarthritis, Hip with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Multicenter, independent study of Synolis VA 80/160 over a period of 6 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single guided intra-articular injection of SYNOLIS VA 80/160
Device: SYNOLIS VA 80/160
SYNOLIS VA 80/160 (hyaluronic acid 80 mg, sorbitol 160 mg)
Evolution of the Oxford Hip Score (OXFORD 12)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Time frame: 6 months (M6)
Evolution of the Oxford Hip Score (OXFORD 12)
Oxford Hip Score (OXFORD 12) composed of 12 questions measuring pain and hip function. Question includes 5 possible answers corresponding to a value from 1 to 5, with 5 representing the highest level of severity, and 1, the total or almost total absence of symptoms.
Time frame: Month 3, Month 3 to Month 6
Self-assessment symptoms evolution
7-point Likert scale (-3 to +3)
Time frame: Month 3, Month 3 to Month 6
MCID Oxford Hip Score (OXFORD 12)
Minimum clinically important difference on the Oxford Hip Score (OXFORD 12)
Time frame: Month 3, Month 3 to Month 6
Hip prosthesis placement after the injection
Number of Participants with Hip prosthesis placement
Time frame: Month 6
Safety and tolerability of SYNOLIS VA 80/160
Serious adverse event occurrence
Time frame: Month 6
Started May 2024 (actual). Primary completion is estimated for Apr 2027, 35 months after the start.
Of 227 interventional studies with no phase under Osteoarthritis, Hip, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 52. This study's planned 35 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aptissen SA